肝細胞癌の治療のためのトレメリムマブ
Miguel Sogbe1, Paloma Sangro2,3, Manuel de la Torre-Aláez2,3
1Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra, Pamplona, Spain.
Expert opinion on biological therapy
|August 20, 2025
まとめ
トレメリムマブは,抗CTLA-4抗体で,肝細胞癌の治療に変化をもたらしました. これは,特に高度なHCCの併用療法において有望であり,初期の段階を探索する研究が進行中である.
科学分野:
- 肝細胞がん (HCC) 研究
- 腫瘍学における免疫療法
- 臨床薬理学
背景:
- 肝細胞癌 (HCC) は,世界の主要な癌死亡原因です.
- HCCに対する従来のチロシンキナーゼ阻害剤の有効性は限られている.
- 免疫療法は 先進的なHCC治療に革命をもたらしました
研究 の 目的:
- HCCにおけるトレメリムマブの薬理学,有効性,安全性を検討する.
- HCCの様々な段階におけるトレメリムマブの役割を調査する.
- 進行中の試験とHCCにおけるトレメリムマブの将来の方向性について議論する.
主な方法:
- トレメリムマブの薬理学的分析
- 臨床試験の証拠のまとめ (単療法と併用療法)
- 進行中の研究と将来の展望のレビュー
主要な成果:
- トレメリムマブは,特にドゥルヴァルマブとの併用で,HCCの治療を改造しました.
- この組み合わせは,良好な安全性プロファイルを持つ耐久的な免疫反応を誘発します.
- トレメリムマブの早期および中期のHCCを調査する.
結論:
- トレメリムマブは,高度なHCC管理における重要な薬剤です.
- HCCにおけるネオアジュバントおよびコンバージョン療法の可能性
- HCCにおけるトレメリムマブの使用を最適化するための予測バイオマーカーの必要性
さらに関連する動画
関連する概念動画
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231